drugset / Trial / NCT05049525

Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease

NCT05049525

Phase 2 Terminated 16 enrolled Montreal Heart Institute
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will evaluate the response of itraconazole and terbinafine therapy compared to placebo in patients with mild to moderate Crohn's disease (CD).

Timeline

Start
2022-02-22
Primary completion
2024-02-28
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Comparator Itraconazole Small molecule 200 mg Oral
Comparator Terbinafine Small molecule 250 mg Oral

Indications